NCT06682572View on ClinicalTrials.gov

A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 30, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

October 31, 2027

Conditions
Low Grade Serous Ovarian CancerOvarian Cancer
Interventions
DRUG

Avutometinib (VS-6766) + Defactinib (VS-6063)

combination therapy

Trial Locations (5)

464-8681

RECRUITING

Aichi Cancer Center Hospital, Nagoya

830-0011

RECRUITING

Kurume University Hospital, Kurume

514-8507

RECRUITING

Mie University Hospital, Tsu

980-8574

RECRUITING

Tohoku University Hospital, Sendai

105-0003

RECRUITING

Jikei University Hospital, Minato

All Listed Sponsors
collaborator

Japanese Gynecologic Oncology Group

OTHER

lead

Verastem, Inc.

INDUSTRY